Senicapoc KCa3.1 Inhibition Stroke Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke are limited in efficacy and often require administration within a narrow temporal window, failing to effectively modulate the neuroimmune response and provide sustained anti-inflammatory effects.
Innovation Solution
Senicapoc, a potent and selective inhibitor of the calcium-activated potassium channel KCa3.1, is administered to cross the blood-brain barrier, reducing nitric oxide and interleukin-1β production, thereby exerting a neuroprotective effect and attenuating stroke-induced injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If current stroke treatments are used, then treatment can be administered, but the therapeutic window is narrow (three to six hours) and efficacy is limited
Solution Approach 1:
The patent changes the temporal parameter of treatment by targeting the neuroimmune response pathway that remains active beyond the traditional therapeutic window. Senicapoc continues to exert neuroprotective effects for at least 24 hours by inhibiting KCa3.1 channels, thereby extending the effective treatment window from 3-6 hours to potentially 24 hours or more.
Solution Approach 2:
The patent introduces senicapoc as an intermediary agent that modulates the neuroimmune response through KCa3.1 channel inhibition. This intermediary mechanism provides sustained anti-inflammatory effects and neuroprotection, overcoming the limitations of direct thrombolysis or other acute interventions that require immediate administration.
2Duration of action of stationary object
If current stroke treatments are used, then treatment can be administered, but sustained anti-inflammatory effects are not achieved
Solution Approach 1:
The patent achieves continuous useful action by targeting the neuroimmune response pathway that persists throughout the inflammatory phase of stroke. Senicapoc maintains sustained anti-inflammatory effects for at least 24 hours by continuously inhibiting KCa3.1 channels in microglia and other immune cells, thereby providing ongoing neuroprotection throughout the critical inflammatory period.
Solution Approach 2:
The patent changes the temporal duration parameter of anti-inflammatory effect from transient (current treatments) to sustained (至少24 hours). This is achieved by targeting the underlying neuroimmune mechanism rather than just the acute symptoms, allowing prolonged therapeutic action.
3Reliability
If microglia are activated in response to ischemia, then immune response is mounted, but neuroinflammation causes additional injury
Solution Approach 1:
The patent converts the harmful neuroinflammatory response into a beneficial outcome by selectively modulating microglial activation. Instead of completely suppressing microglia (which would eliminate protective functions), senicapoc fine-tunes the response to reduce harmful inflammation while preserving beneficial neuroimmune functions, thereby converting the double-edged sword of microglial activation into a net benefit.
Solution Approach 2:
The patent applies local quality by selectively targeting specific aspects of microglial activation through KCa3.1 channel inhibition. This selective modulation allows different regions and functions of the neuroimmune response to be differentially regulated, reducing harmful inflammation in affected areas while maintaining protective functions elsewhere.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Senicapoc effectively reduces stroke-induced injury and neuroinflammation, offering a broader therapeutic window beyond the traditional three to six-hour treatment window and demonstrating safety with minimal side effects, while maintaining selectivity for KCa3.1 channels.
Implementation Method 1
Senicapoc is a potent and selective inhibitor of the calcium-activated potassium channel KCa3.1
Implementation Method 2
the ability of senicapoc to cross the blood-brain barrier
Implementation Method 3
inhibiting KCa3.1 reduces microglial synthesis of enzymes involved in production of eicosanoids (COX-2) and nitric oxide (iNOS)
Implementation Method 4
inhibition reduces production and release of nitric oxide (NO) and interleukin 1β (IL-1β) from appropriately stimulated microglia
Data Source
AI summary
Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major component of stroke pathophysiology. The calcium activated potassium channel KCa3.1 is expressed selectively in the injured CNS by microglia, and KCa3.1 function has been implicated in proinflammatory activation of microglia. KCa3.1 is further implicated in the pathophysiology of ischemia/reperfusion (stroke) related brain injury. Senicapoc, an investigational drug with a proven safety profile and shown to cross the blood-brain barrier, is a potent and selective KCa3.1 inhibitor that intervenes in the inflammation cascade that follows ischemia/reperfusion, and is a potential treatment for stroke.